Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent

Complete portfolio of Company's WallFlex Stent family of self-expanding metal stents now available in U.S., Europe and other international markets

NATICK, Massachusetts and LONDON, November 23 - Boston Scientific Corporation (NYSE: BSX) today announced that it has
received 510(k) clearance from the U.S. Food and Drug Administration (FDA)
and CE Mark approval to market its WallFlex(R) Fully Covered Esophageal Stent
for the treatment of malignant esophageal strictures (obstructions) caused by
tumors in patients with resectable or non-resectable esophageal cancer.

(Photo: www.newscom.com/cgi-bin/prnh/20091120/NE13563)

The WallFlex(R) Partially Covered Esophageal Stent was cleared by the FDA
and received CE Mark in 2008. Both stents — along with the complete WallFlex
Stent family of self-expanding metal stents (SEMS) — will be available for
hands-on demonstration at the GASTRO 2009 conference, which is being held
November 21-25 in London.

"The low profile delivery system (18.5 Fr) of the WallFlex Esophageal
Stents has allowed me to traverse tight strictures, facilitating stent
placement within malignancies that, in the past, needed to be pre-dilated,"
said Drew Schembre, M.D., Chief of Gastroenterology at Virginia Mason Medical
Center in Seattle, Washington. "Moreover, the fully covered option may be a
viable choice for patients with operable esophageal cancer who are undergoing
chemotherapy and radiation treatment in preparation for surgery."

Patients with obstructions due to esophageal cancer may have difficulty
swallowing, resulting in severely limited quality of life. Complete blockages
of the esophagus can prevent liquid consumption. The WallFlex Esophageal
Stent allows physicians to re-establish patency (openness) of the esophagus,
enabling resumption of oral intake.

The WallFlex Fully and Partially Covered Stents employ a proprietary
Permalume(R) silicone covering designed to prevent tumor ingrowth, seal
concurrent esophageal fistulas and help reduce food impaction. The stents'
progressive-step, flared ends are designed to reduce the risk of migration
and may assist in anchoring the fully covered stent within the esophageal
lumen. The multiple wire-braided construction is engineered to allow the
stent to adjust to forces within the esophagus such as peristalsis
(involuntary contractions) and strictures. In addition, the WallFlex Fully
Covered Stent may be reconstrained up to 75 percent deployment.

"The availability of the complete line of WallFlex Fully and Partially
Covered Esophageal Stents represents a tremendous milestone for Boston
Scientific," said Michael Phalen, President, Boston Scientific Endoscopy.
"This advanced line of esophageal stents is designed to improve the quality
of life for the thousands of patients suffering from esophageal cancer. We
are pleased that our entire WallFlex Stent family - biliary, enteral and now
esophageal - is available in the U.S., Europe and other strategic
international markets. This underscores our mission to meet the high
expectations of our customers and deliver a complete range of innovative
treatment options to diagnose, palliate and treat patients with diseases of
the gastrointestinal tract."

Symposium at GASTRO 2009

Boston Scientific will host a symposium titled "Esophageal Stenting:
Changing Algorithms, Changing Outcomes" on Tuesday, November 24 at 7:00 a.m.
at GASTRO 2009 in London. The event will be moderated by Professor Horst
Neuhaus of Evangelisches Krankenhaus in Düsseldorf, Germany. Panelists and
topics include Dr. Marc Giovannini, Institut Paoli-Calmettes in Marseille,
France, who will discuss advancing treatment options; Professor Jacques
Devière, Erasme Hospital in Brussels, Belgium, who will address benign
conditions and expanding the role of stents; and Professor Peter Siersema,
University Medical Center Utrecht in The Netherlands who will discuss
minimizing reintervention rates in stenting.

About Boston Scientific

Boston Scientific is a worldwide developer, manufacturer and marketer of
medical devices whose products are used in a broad range of interventional
medical specialties. For more information, please visit:
www.bostonscientific.com.

About Boston Scientific Endoscopy

Boston Scientific Endoscopy develops innovative technology for less
invasive, more efficient gastrointestinal procedures.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements. Boston Scientific
wishes to caution the reader of this press release that actual results may
differ from those discussed in the forward-looking statements and may be
adversely affected by, among other things, risks associated with new product
development and commercialization, clinical trials, intellectual property,
regulatory approvals, competitive offerings, Boston Scientific's overall
business strategy, and other factors described in Boston Scientific's filings
with the Securities and Exchange Commission.

    CONTACT:  Geraldine Varoqui
              Boston Scientific
              Public Relations International
              +49-170-782-85-58
              varoquig@bsci.com

Geraldine Varoqui of Boston Scientific Corporation, +49-170-782-85-58, varoquig at bsci.com